Empagliflozin Indications and Usage

Primary Indications

The American College of Cardiology recommends empagliflozin 10 mg once daily as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1
The American College of Cardiology indicates that empagliflozin is used to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease 1

Empagliflozin reduced hospitalization for heart failure by 35% in patients with type 2 diabetes 2
In patients with prevalent kidney disease at baseline, empagliflozin reduced the risk of a prespecified renal composite outcome by 50% compared to placebo (HR 0.50; 95% CI 0.32-0.77) 2

The recommended starting dose is 10 mg once daily, taken in the morning, with or without food, according to the American College of Cardiology 1
No dose titration is needed for cardiovascular or renal risk reduction benefits, as stated by the American College of Cardiology 3

The American College of Cardiology advises not to initiate empagliflozin if eGFR is below 45 mL/min/1.73 m² 1
Empagliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or on dialysis, as recommended by the American College of Cardiology 1

The American College of Cardiology states that empagliflozin is contraindicated in patients with a history of serious hypersensitivity reaction to empagliflozin or any of the excipients in Jardiance 1

The American College of Cardiology recommends monitoring for hypotension, especially in patients with renal impairment, elderly patients, those with low systolic blood pressure, or patients on diuretics 1
Consider reducing doses of insulin or insulin secretagogues when initiating empagliflozin to reduce risk of hypoglycemia, as advised by the American College of Cardiology 1
Discontinue at least 3 days before planned surgery to prevent postoperative ketoacidosis, according to the American College of Cardiology 1